Réjean Lapointe is the new in-charge for Cancer Axis

Version imprimable
Partager
April 13, 2018
Réjean Lapointe

It is with great pleasure that the management of the Research Center of the University Hospital of Montreal (CRCHUM) informs you of the appointment of Réjean Lapointe as In-Charge of the Cancer Axis. He assumed this new position since April 1, 2018.

Réjean Lapointe succeeds Anne-Marie Mes-Masson who has implemented, directed and developed the Cancer Axis in a remarkable way since the very beginning of the CRCHUM.

Réjean Lapointe has been a regular researcher at CRCHUM since 2002, an active member of the Montreal Cancer Institute and a Professor in the Department of Medicine at the Université de Montréal. He is well known for his translational research work in immuno-oncology and immunotherapy.

"We are convinced that Réjean Lapointe's thorough knowledge of the axis, vision of excellence and unifying qualities will allow him to pursue the scientific development of the Cancer Axis with great success", says Vincent Poitout, Director of CHUM Research Center.

Biography

Réjean Lapointe is a researcher specializing in cancer immunotherapy at the CRCHUM and a Professor at the Faculty of Medicine of the Université de Montréal and the Montreal Cancer Institute. Following his PhD in Biochemistry from Laval University in 1997, he continued his training in the laboratories of the National Cancer Institute, USA. For the past ten years, he has continued his work in basic and applied research. The main goal of his research is to understand the basic mechanisms of the immune system (T and B lymphocytes), to unravel the relationship between different cancers and the immune system, to identify new immunological targets for cancer therapy and to develop new approaches for vaccination and cancer immunotherapy. Réjean Lapointe is the head of the breast cancer bank of the Quebec Research Fund - Quebec Health Research Network (FRQS), a member of the Terry Fox Research Institute and the National Center of Excellence for Biotherapeutics for cancer treatment. In addition, he has more than 60 publications in immunology, oncology and microbiology.